Search
Jazz Pharmaceuticals PLC
JAZZAdd to Watchlist
240.830USD
-5.040-2.05%
Close 09-15 16:00（ET）
15.61BMarket Cap
584.08P/E TTM
Jazz Pharmaceuticals PLC (JAZZ) Revenue Performance
Updated: Jun 30, 2026Last year, Jazz Pharmaceuticals PLC generated 1.66B USD for its biggest-performing segment, Xywav. The United States made the largest contribution, accounting for 3.83B USD last year. For the latest quarter, Jazz Pharmaceuticals PLC reported the revenue of 471.20M USD for the period ending 2026-06-30, which came from the top-performing segment, Xywav. United States contributed the highest revenue, at 1.08B USD.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
Xywav
Epidiolex/epidyolex
Rylaze
Zepzelca
High-sodium oxybate AG royalty revenue
Defitelio/defibrotide
Vyxeos
Xyrem
Modeyso
Royalties and contract revenues
Ziihera
sativex
Other Revenue
Oxybate
Sunosi
Erwianaze/Erwinase
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Xywav
1.66B(38.83%)
1.47B(36.21%)
1.27B(33.20%)
--(--)
--(--)
--(--)
--(--)
Epidiolex/epidyolex
1.06B(24.82%)
972.42M(23.90%)
845.47M(22.05%)
--(--)
--(--)
--(--)
--(--)
Rylaze
402.92M(9.44%)
410.85M(10.10%)
394.23M(10.28%)
281.66M(7.70%)
85.63M(2.77%)
--(--)
--(--)
Zepzelca
307.31M(7.20%)
320.32M(7.87%)
289.53M(7.55%)
269.91M(7.38%)
246.81M(7.98%)
90.38M(3.82%)
--(--)
High-sodium oxybate AG royalty revenue
211.72M(4.96%)
217.57M(5.35%)
75.92M(1.98%)
--(--)
--(--)
--(--)
--(--)
Defitelio/defibrotide
199.39M(4.67%)
216.56M(5.32%)
184.00M(4.80%)
194.29M(5.31%)
197.93M(6.40%)
195.84M(8.29%)
172.94M(8.00%)
Vyxeos
146.71M(3.44%)
162.59M(4.00%)
147.50M(3.85%)
127.98M(3.50%)
134.06M(4.33%)
121.11M(5.12%)
121.41M(5.62%)
Xyrem
146.03M(3.42%)
233.82M(5.75%)
569.73M(14.86%)
--(--)
--(--)
--(--)
--(--)
Modeyso
48.04M(1.13%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Royalties and contract revenues
34.01M(0.80%)
30.21M(0.74%)
21.34M(0.56%)
17.95M(0.49%)
15.24M(0.49%)
16.91M(0.72%)
26.16M(1.21%)
Ziihera
24.81M(0.58%)
1.05M(0.03%)
--(--)
--(--)
--(--)
--(--)
--(--)
sativex
16.28M(0.38%)
18.88M(0.46%)
19.67M(0.51%)
--(--)
--(--)
--(--)
--(--)
Other Revenue
14.17M(0.33%)
11.47M(0.28%)
13.85M(0.36%)
6.64M(0.18%)
9.80M(0.32%)
6.84M(0.29%)
17.55M(0.81%)
Oxybate
--(--)
--(--)
--(--)
1.98B(54.08%)
--(--)
1.76B(74.34%)
1.64B(75.98%)
Sunosi
--(--)
--(--)
--(--)
782.07M(21.37%)
2.34B(75.48%)
28.33M(1.20%)
3.71M(0.17%)
Erwianaze/Erwinase
--(--)
--(--)
--(--)
--(--)
69.38M(2.24%)
147.14M(6.23%)
177.47M(8.21%)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
Europe
All Others
All Other
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
United States
3.83B(89.78%)
3.66B(89.95%)
3.49B(91.02%)
3.37B(92.10%)
2.82B(91.14%)
2.14B(89.08%)
1.97B(89.01%)
Europe
341.12M(7.99%)
312.71M(7.69%)
269.24M(7.02%)
239.64M(6.55%)
230.16M(7.44%)
175.21M(7.28%)
150.20M(6.80%)
All Others
94.87M(2.22%)
96.14M(2.36%)
74.98M(1.96%)
49.36M(1.35%)
43.84M(1.42%)
43.82M(1.82%)
46.24M(2.09%)
All Other
--(--)
--(--)
--(--)
--(--)
--(--)
43.82M(1.82%)
46.24M(2.09%)